European Patent Office issues key patent to TiGenix for expanded adipose-derived stem cell compositions

23-Jan-2015 - Belgium

TiGenix NV announced that the European Patent Office (EPO) has issued European Patent EP2292736 relating to an adipose-derived stem cell composition. The patent is entitled "Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue". The claims of the granted patent cover both a specified population of expanded adipose-derived multipotent cells and their therapeutic uses, as well as pharmaceutical compositions of such cells.

TiGenix is developing injectable products from its proprietary platform of allogeneic expanded adipose-derived stem cells (eASCs) for inflammatory and autoimmune diseases. Cx601 is a solution of allogeneic eASCs for local injection currently in Phase III of clinical development for the treatment of complex perianal fistulas in patients with Crohn's disease. Clinical results from the on-going European Phase III trial are expected in the third quarter of 2015, and, if positive, may allow the company to file for Marketing Authorisation in Europe. Cx611 is an intravenously-administered product of allogeneic eASCs, which TiGenix is currently developing for patients with early rheumatoid arthritis and for patients with severe sepsis.

"This European patent further strengthens our intellectual property position in the field of expanded adipose-derived stem cell compositions and their therapeutic uses", said Wilfried Dalemans, Chief Technical Officer of TiGenix. "The grant of this patent advances our leading position in bringing adipose-derived stem cell therapeutics to patients."

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances